Browsing Tag

Alector LLC

Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of…

Eli Pacheco Nov 13, 2021 0

Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated…

Health

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference…

Eli Pacheco Nov 4, 2021 0

Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a…

Health

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical…

Eli Pacheco Jul 29, 2021 0

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients Treatment with AL001 Slowed Clinical Progression by 47% Based on the CDR® plus NACC FTLD-SB Scale Relative to…

Health

Alector and GSK announce global collaboration in immuno-neurology for two clinical…

Eli Pacheco Jul 3, 2021 0

Alector and GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral…